Asthma, green light from Aifa for a new drug against the severe form. The Italian Medicines Agency (AIFA) has in fact approved the reimbursement of the monoclonal antibody tezepelumab.
The drug is indicated as adjunctive maintenance therapy in patients aged 12 years and older with the disease and who are not adequately controlled despite the use of high-dose inhaled corticosteroids. In Italy there are 3 million people affected by asthma; 10% of them develop severe uncontrolled asthma.